| 229 |
increased |
ionotropic glutamate receptor activity
(GO:0004970)
|
ionotropic glutamate receptor complex
(GO:0008328)
|
875: Binding of agonist, Ionotropic glutamate receptors
|
| 230 |
increased |
hormone biosynthetic process
(GO:0042446)
|
Luteinizing hormone
(CHEBI:81568)
|
414: Increase, Luteinizing hormone (LH)
|
| 231 |
abnormal |
sex ratio
(MESH:D012744)
|
|
417: skewed, sex ratio
|
| 232 |
functional change |
|
glomerular basement membrane
(UBERON:0005777)
|
421: Increased, glomerular rupture and renal hemorrhaging
|
| 374 |
decreased |
spindle organization
(GO:0007051)
|
spindle
(GO:0005819)
|
721: Disorganization, Meiotic Spindle
|
| 234 |
increased |
Nephropathy
(HP:0000112)
|
|
422: Increased, nephropathy
|
| 235 |
decreased |
sodium:iodide symporter activity
(GO:0008507)
|
sodium/iodide cotransporter
(PR:000015171)
|
424: Inhibition, Na+/I- symporter (NIS)
|
| 371 |
abnormal |
chromosome movement towards spindle pole
(GO:0051305)
|
chromosome
(GO:0005694)
|
752: Altered, Meiotic chromosome dynamics
|
| 237 |
abnormal |
abnormal neuron morphology
(MP:0002882)
|
|
851: Decrease of GABAergic interneurons
|
| 238 |
decreased |
secretion
(GO:0046903)
|
very-low-density lipoprotein
(CHEBI:39027)
|
450: Decrease, Very low-density lipoprotein export capacity
|
| 239 |
decreased |
gene expression
(GO:0010467)
|
phosphoenolpyruvate carboxykinase, cytosolic [GTP]
(PR:000012416)
|
216: Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)
|
| 240 |
increased |
fatty acid transport
(GO:0015908)
|
fatty acid
(CHEBI:35366)
|
465: Increased, Fatty acid influx
|
| 241 |
increased |
gene expression
(GO:0010467)
|
low-density lipoprotein receptor
(PR:000009744)
|
466: Up Regulation, LDLR (low density lipoprotein receptor)
|
| 242 |
increased |
receptor-mediated endocytosis
(GO:0006898)
|
low-density lipoprotein
(CHEBI:39026)
|
467: Increased, LDL uptake
|
| 243 |
increased |
gene expression
(GO:0010467)
|
cytochrome P450 1A1
(PR:000006101)
|
80: Up Regulation, CYP1A1
|
| 244 |
decreased |
signaling
(GO:0023052)
|
nuclear receptor subfamily 1 group I member 3
(PR:000011398)
|
456: Suppression, Constitutive androstane receptor, NR1I3
|
| 245 |
increased |
signaling
(GO:0023052)
|
sterol regulatory element-binding protein 1
(PR:000015611)
|
457: Activation, SREBF1
|
| 246 |
increased |
triglyceride biosynthetic process
(GO:0019432)
|
triglyceride
(CHEBI:17855)
|
454: Increased, Triglyceride formation
|
| 247 |
increased |
gene expression
(GO:0010467)
|
fatty acid synthase
(PR:000007348)
|
463: Up Regulation, FAS
|
| 248 |
increased |
acetyl-CoA carboxylase activity
(GO:0003989)
|
acetyl-CoA carboxylase 1
(PR:000003596)
|
470: Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)
|
| 249 |
decreased |
signaling
(GO:0023052)
|
hepatocyte nuclear factor 4-alpha
(PR:000008654)
|
461: Suppression, HNF4alpha
|
| 250 |
decreased |
signaling
(GO:0023052)
|
hepatocyte nuclear factor 3-beta
(PR:000007603)
|
471: Inhibition, FoxA2
|
| 251 |
decreased |
gene expression
(GO:0010467)
|
carnitine O-palmitoyltransferase 1, liver isoform
(PR:000005835)
|
472: Down Regulation, CPT1A
|
| 252 |
decreased |
gene expression
(GO:0010467)
|
hydroxymethylglutaryl-CoA synthase, mitochondrial
(PR:000008638)
|
474: Down Regulation, HMGCS2
|
| 254 |
increased |
signaling
(GO:0023052)
|
nuclear factor erythroid 2-related factor 2
(PR:000011170)
|
478: Activation, NRF2
|